ELITE PHARMACEUTICALS INC /NV/ Quarterly Other Liabilities, Noncurrent in USD from Q1 2011 to Q2 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
Summary
Elite Pharmaceuticals Inc /Nv/ quarterly Other Liabilities, Noncurrent history and growth rate from Q1 2011 to Q2 2022.
  • Elite Pharmaceuticals Inc /Nv/ Other Liabilities, Noncurrent for the quarter ending June 30, 2022 was $40.6K, a 6.17% increase year-over-year.
Other Liabilities, Noncurrent, Quarterly (USD)
Other Liabilities, Noncurrent, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2022 $40.6K +$2.36K +6.17% Jun 30, 2022 10-Q 2022-08-15
Q1 2022 $38.8K +$1.15K +3.06% Mar 31, 2022 10-K 2023-06-29
Q4 2021 $38.2K +$1.12K +3.02% Dec 31, 2021 10-Q 2022-02-14
Q3 2021 $38.8K +$2.25K +6.17% Sep 30, 2021 10-Q 2021-11-15
Q2 2021 $38.2K +$2.22K +6.17% Jun 30, 2021 10-Q 2021-08-16
Q1 2021 $37.6K +$2.19K +6.17% Mar 31, 2021 10-K 2022-06-29
Q4 2020 $37.1K +$2.15K +6.16% Dec 31, 2020 10-Q 2021-02-16
Q3 2020 $36.5K +$2.12K +6.17% Sep 30, 2020 10-Q 2020-11-16
Q2 2020 $36K +$2.11K +6.24% Jun 30, 2020 10-Q 2020-08-14
Q1 2020 $35.4K -$11K -23.6% Mar 31, 2020 10-K 2021-06-14
Q4 2019 $34.9K -$11K -23.9% Dec 31, 2019 10-Q 2020-02-10
Q3 2019 $34.4K -$9.9K -22.3% Sep 30, 2019 10-Q 2019-11-12
Q2 2019 $33.9K -$7.28K -17.7% Jun 30, 2019 10-Q 2019-08-09
Q1 2019 $46.4K +$5.26K +12.8% Mar 31, 2019 10-K 2020-06-30
Q4 2018 $45.9K +$6.3K +15.9% Dec 31, 2018 10-Q 2019-02-11
Q3 2018 $44.3K +$7.33K +19.8% Sep 30, 2018 10-Q 2018-11-09
Q2 2018 $41.1K +$6.78K +19.7% Jun 30, 2018 10-Q 2018-08-09
Q1 2018 $41.1K +$9.37K +29.5% Mar 31, 2018 10-K 2019-06-21
Q4 2017 $39.6K +$10.4K +35.7% Dec 31, 2017 10-Q 2018-02-09
Q3 2017 $37K +$1.72K +4.87% Sep 30, 2017 10-Q 2017-11-09
Q2 2017 $34.4K -$6.97K -16.9% Jun 30, 2017 10-Q 2017-08-09
Q1 2017 $31.8K -$15.7K -33% Mar 31, 2017 10-K 2018-06-14
Q4 2016 $29.2K -$579K -95.2% Dec 31, 2016 10-Q 2017-02-09
Q3 2016 $35.3K -$514K -93.6% Sep 30, 2016 10-Q 2016-11-09
Q2 2016 $41.3K -$522K -92.7% Jun 30, 2016 10-Q 2016-08-09
Q1 2016 $47.4K -$582K -92.5% Mar 31, 2016 10-K 2017-06-14
Q4 2015 $608K +$144K +30.9% Dec 31, 2015 10-Q 2016-02-09
Q3 2015 $549K +$168K +44.1% Sep 30, 2015 10-Q/A 2015-12-30
Q2 2015 $563K +$244K +76.6% Jun 30, 2015 10-Q/A 2015-12-30
Q1 2015 $629K +$498K +380% Mar 31, 2015 10-K 2016-06-15
Q4 2014 $464K +$366K +372% Dec 31, 2014 10-Q 2015-02-17
Q3 2014 $381K +$285K +297% Sep 30, 2014 10-Q 2014-11-14
Q2 2014 $319K +$225K +240% Jun 30, 2014 10-Q 2014-08-14
Q1 2014 $131K +$39.6K +43.2% Mar 31, 2014 10-K 2015-06-15
Q4 2013 $98.3K +$7.84K +8.66% Dec 31, 2013 10-Q 2014-02-14
Q3 2013 $96.1K +$6.58K +7.35% Sep 30, 2013 10-Q 2013-11-14
Q2 2013 $93.8K +$5.36K +6.06% Jun 30, 2013 10-Q 2013-08-14
Q1 2013 $91.6K +$4.17K +4.77% Mar 31, 2013 10-K 2014-06-30
Q4 2012 $90.5K +$12.1K +15.5% Dec 31, 2012 10-Q 2013-02-14
Q3 2012 $89.5K +$14.3K +19.1% Sep 30, 2012 10-Q 2012-11-14
Q2 2012 $88.5K Jun 30, 2012 10-Q 2012-08-14
Q1 2012 $87.4K +$11.9K +15.8% Mar 31, 2012 10-K 2013-06-21
Q4 2011 $78.4K Dec 31, 2011 10-Q 2012-02-14
Q3 2011 $75.2K Sep 30, 2011 10-Q 2011-11-14
Q1 2011 $75.5K Mar 31, 2011 10-K 2012-06-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.